EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

THE EFFECTIVENESS OF SODIUM–GLUCOSE COTRANSPORTER-2 INHIBITOR THERAPY IN SLOWING THE PROGRESSION OF CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES

Claudia Monica, Claudya Meylinia, Eric Fernandez

The Indonesian Journal of General Medicine · 09.11.2026 · 44 (2) · 477-541

DOI: 10.70070/4356mn02 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The Indonesian Journal of General Medicine, online erschienen am 09.11.2026. Verfasst von Claudia Monica und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Chronic kidney disease (CKD) affects an estimated 788 million adults and is now the ninth leading cause of death worldwide, yet for decades renin–angiotensin system (RAS) blockade was the only pharmacological strategy proven to slow its progression. Sodium–glucose cotransporter-2 inhibitors (SGLT2i) have since been evaluated in dedicated kidney trials, cardiovascular outcome trials (CVOTs), heart failure trials and real-world cohorts, but these sources use heterogeneous definitions of kidney progression and enrol different populations. This review aimed to quantify the effectiveness of SGLT2i in slowing CKD progression by integrating randomised and real-world evidence, and to establish whether the effect is modified by diabetes status, baseline kidney function or trial population.

Methods

The review followed the PRISMA 2020 statement. PubMed, Europe PMC, Semantic Scholar and ClinicalTrials.gov were searched from January 2011 to November 2026 (≤15 years) and supplemented by citation searching. Randomised controlled trials (RCTs), comparative studies, cohort studies and case series comparing an SGLT2i with placebo or non-SGLT2i care and reporting a kidney progression outcome were eligible; systematic reviews and meta-analyses were excluded from the characteristics tables but retained for the Discussion. Primary outcomes were a kidney-specific composite outcome and the annualised estimated glomerular filtration rate (eGFR) slope; secondary outcomes were the primary cardiorenal composite, kidney failure, all-cause mortality, cardiovascular death or hospitalisation for heart failure (HHF), serious acute kidney injury (AKI) and albuminuria. Risk of bias was assessed with RoB 2 and ROBINS-I. Effects were pooled with DerSimonian–Laird random-effects models with Hartung–Knapp–Sidik–Jonkman (HKSJ) adjustment and 95% prediction intervals (PI), and certainty was graded with GRADE.

Results

Twenty-three studies were included (14 RCTs, n = 89,705; nine cohort studies, n = 206,423; 39 reports). SGLT2i reduced the kidney-specific composite outcome by 34% (hazard ratio [HR] 0.66; 95% CI 0.59–0.75; 12 RCTs; I² = 61%; PI 0.45–0.97; high certainty), with consistent effects in CKD-dedicated trials (HR 0.66; 0.59–0.74; I² = 18%) and type 2 diabetes CVOTs (HR 0.58; 0.51–0.65) and an attenuated effect in heart failure trials (HR 0.81; 0.59–1.10; P for subgroup difference = 0.09). In CKD-dedicated trials, SGLT2i reduced the primary cardiorenal composite (HR 0.70; 0.64–0.77), all-cause mortality (HR 0.85; 0.74–0.98), cardiovascular death or HHF (HR 0.75; 0.68–0.83) and serious AKI (HR 0.80; 0.68–0.95); kidney failure was reduced in RCTs (HR 0.63; 0.54–0.74). SGLT2i slowed eGFR decline by 1.61 mL/min/1.73 m² per year (95% CI 1.32–1.91; 10 RCT estimates), above the 0.75 mL/min/1.73 m² per year threshold in every trial, and lowered albuminuria by 19% (ratio 0.81; 0.76–0.86). Benefits were similar with and without diabetes (HR 0.64 vs 0.66; P for interaction = 0.92) and across baseline eGFR strata, including eGFR

Zitieren

APA

Monica, C., Meylinia, C., & Fernandez, E. (2026). THE EFFECTIVENESS OF SODIUM–GLUCOSE COTRANSPORTER-2 INHIBITOR THERAPY IN SLOWING THE PROGRESSION OF CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES. The Indonesian Journal of General Medicine, 44(2), 477-541. https://doi.org/10.70070/4356mn02

Vancouver

Monica C, Meylinia C, Fernandez E. THE EFFECTIVENESS OF SODIUM–GLUCOSE COTRANSPORTER-2 INHIBITOR THERAPY IN SLOWING THE PROGRESSION OF CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES. The Indonesian Journal of General Medicine. 2026;44(2):477-541. doi:10.70070/4356mn02

BibTeX
@article{Monica2026,
  author = {Monica, Claudia and Meylinia, Claudya and Fernandez, Eric},
  title = {THE EFFECTIVENESS OF SODIUM–GLUCOSE COTRANSPORTER-2 INHIBITOR THERAPY IN SLOWING THE PROGRESSION OF CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES},
  journal = {The Indonesian Journal of General Medicine},
  year = {2026},
  volume = {44},
  number = {2},
  pages = {477--541},
  doi = {10.70070/4356mn02}
}
Kostenlos starten →